Summary
Global Markets Direct’s, ‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016’, provides an overview of the B-Cell Non-Hodgkin Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Altor BioScience Corporation
Amgen Inc.
arGEN-X BV
Ariad Pharmaceuticals, Inc.
Arrien Pharmaceuticals, LLC
Arvinas, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Bayer AG
BeiGene, Ltd.
BIND Therapeutics, Inc.
Bio-Path Holdings, Inc.
Biocon Limited
Biogenomics Limited
Biothera, Inc.
Bluebird bio, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cell>Point, L.L.C.
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
Constellation Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
Dynavax Technologies Corporation
eFFECTOR Therapeutics, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Genor BioPharma Co., Ltd.
Genosco
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Immune Design Corp.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovaccine, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Inflection Biosciences Limited
JHL Biotech, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Karus Therapeutics Limited
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Les Laboratoires Servier SAS
LFB S.A.
Mabion SA
mAbxience S.A.
MedImmune, LLC
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mirna Therapeutics, Inc.
Molecular Templates Inc.
Molplex Ltd.
MorphoSys AG
Neumedicines Inc.
Nimbus Therapeutics, LLC
Nordic Nanovector ASA
Novartis AG
NovImmune SA
Onconova Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
OXIS International, Inc.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Portola Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals, Inc.
Respiratorius AB
Rhizen Pharmaceuticals S.A.
Sandoz International GmbH
Sanofi
Seattle Genetics, Inc.
Selvita S.A.
Shanghai Henlius Biotech Co., Ltd.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Taiho Pharmaceutical Co., Ltd.
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
The International Biotechnology Center (IBC) Generium
Theravectys SA
United BioPharma, Inc.
Unum Therapeutics, Inc.
Vivolux AB
'
Table of Contents
Table of Contents 2
Introduction 8
B-Cell Non-Hodgkin Lymphoma Overview 9
Therapeutics Development 10
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 12
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 22
B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 23
B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 27
B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 53
B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 55
B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment 170
Drug Profiles 202
B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates 657
B-Cell Non-Hodgkin Lymphoma - Dormant Projects 1015
B-Cell Non-Hodgkin Lymphoma - Discontinued Products 1028
B-Cell Non-Hodgkin Lymphoma - Product Development Milestones 1033
Appendix 1040
List of Tables
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016 35
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 38
Number of Products under Development by Companies, H1 2016 (Contd..1) 39
Number of Products under Development by Companies, H1 2016 (Contd..2) 40
Number of Products under Development by Companies, H1 2016 (Contd..3) 41
Number of Products under Development by Companies, H1 2016 (Contd..4) 42
Number of Products under Development by Companies, H1 2016 (Contd..5) 43
Number of Products under Development by Companies, H1 2016 (Contd..6) 44
Number of Products under Development by Companies, H1 2016 (Contd..7) 45
Number of Products under Development by Companies, H1 2016 (Contd..8) 46
Number of Products under Investigation by Universities/Institutes, H1 2016 47
Comparative Analysis by Late Stage Development, H1 2016 48
Comparative Analysis by Clinical Stage Development, H1 2016 49
Comparative Analysis by Early Stage Development, H1 2016 50
Comparative Analysis by Unknown Stage Development, H1 2016 51
Products under Development by Companies, H1 2016 52
Products under Development by Companies, H1 2016 (Contd..1) 53
Products under Development by Companies, H1 2016 (Contd..2) 54
Products under Development by Companies, H1 2016 (Contd..3) 55
Products under Development by Companies, H1 2016 (Contd..4) 56
Products under Development by Companies, H1 2016 (Contd..5) 57
Products under Development by Companies, H1 2016 (Contd..6) 58
Products under Development by Companies, H1 2016 (Contd..7) 59
Products under Development by Companies, H1 2016 (Contd..8) 60
Products under Development by Companies, H1 2016 (Contd..9) 61
Products under Development by Companies, H1 2016 (Contd..10) 62
Products under Development by Companies, H1 2016 (Contd..11) 63
Products under Development by Companies, H1 2016 (Contd..12) 64
Products under Development by Companies, H1 2016 (Contd..13) 65
Products under Development by Companies, H1 2016 (Contd..14) 66
Products under Development by Companies, H1 2016 (Contd..15) 67
Products under Development by Companies, H1 2016 (Contd..16) 68
Products under Development by Companies, H1 2016 (Contd..17) 69
Products under Development by Companies, H1 2016 (Contd..18) 70
Products under Development by Companies, H1 2016 (Contd..19) 71
Products under Development by Companies, H1 2016 (Contd..20) 72
Products under Development by Companies, H1 2016 (Contd..21) 73
Products under Development by Companies, H1 2016 (Contd..22) 74
Products under Development by Companies, H1 2016 (Contd..23) 75
Products under Development by Companies, H1 2016 (Contd..24) 76
Products under Development by Companies, H1 2016 (Contd..25) 77
Products under Investigation by Universities/Institutes, H1 2016 78
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 79
B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016 80
B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016 81
B-Cell Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 82
B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 83
B-Cell Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016 84
B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016 85
B-Cell Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016 86
B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016 87
B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016 88
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 89
B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 90
B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H1 2016 91
B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 92
B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 93
B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 94
B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 95
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016 96
B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene, Ltd., H1 2016 97
B-Cell Non-Hodgkin Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016 98
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016 99
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H1 2016 100
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H1 2016 101
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H1 2016 102
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016 103
B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 104
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 105
B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016 106
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016 107
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016 108
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 109
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016 110
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 111
B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016 112
B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 113
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 114
B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016 115
B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016 116
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 117
B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016 118
B-Cell Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016 119
B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 120
B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016 121
B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 122
B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2016 123
B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 124
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2016 125
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016 126
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016 127
B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 128
B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016 129
B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016 130
B-Cell Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 131
B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016 132
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016 133
B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 134
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 135
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016 136
B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016 137
B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 138
B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016 139
B-Cell Non-Hodgkin Lymphoma - Pipeline by JHL Biotech, Inc., H1 2016 140
B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016 141
B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 142
B-Cell Non-Hodgkin Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016 143
B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 144
B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 145
B-Cell Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016 146
B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H1 2016 147
B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2016 148
B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H1 2016 149
B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016 150
B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H1 2016 151
B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016 152
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 153
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016 154
B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 155
B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 156
B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 157
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016 158
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H1 2016 159
B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016 160
B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016 161
B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016 162
B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 163
B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016 164
B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2016 165
B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2016 166
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 167
B-Cell Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H1 2016 168
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016 169
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 170
B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016 171
B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 172
B-Cell Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 173
B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016 174
B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 175
B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2016 176
B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 177
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2016 178
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016 179
B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 180
B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016 181
B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 182
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016 183
B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 184
B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016 185
B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 186
B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2016 187
B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 188
B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 189
B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 190
B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016 191
B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H1 2016 192
B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016 193
B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2016 194
Assessment by Monotherapy Products, H1 2016 195
Assessment by Combination Products, H1 2016 196
Number of Products by Stage and Target, H1 2016 198
Number of Products by Stage and Mechanism of Action, H1 2016 213
Number of Products by Stage and Route of Administration, H1 2016 224
Number of Products by Stage and Molecule Type, H1 2016 226
B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 682
B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H1 2016 1040
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016 1041
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016 1042
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016 1043
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016 1044
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016 1045
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016 1046
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016 1047
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016 1048
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016 1049
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016 1050
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016 1051
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016 1052
B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H1 2016 1053
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016 1054
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016 1055
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016 1056
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016 1057
List of Figures
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016 35
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 37
Number of Products under Investigation by Universities/Institutes, H1 2016 47
Comparative Analysis by Late Stage Development, H1 2016 48
Comparative Analysis by Clinical Stage Development, H1 2016 49
Comparative Analysis by Early Stage Products, H1 2016 50
Assessment by Monotherapy Products, H1 2016 195
Number of Products by Top 10 Targets, H1 2016 197
Number of Products by Stage and Top 10 Targets, H1 2016 197
Number of Products by Top 10 Mechanism of Actions, H1 2016 212
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 212
Number of Products by Routes of Administration, H1 2016 223
Number of Products by Stage and Routes of Administration, H1 2016 223
Number of Products by Top 10 Molecule Types, H1 2016 225
Number of Products by Stage and Top 10 Molecule Types, H1 2016 225
